Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 17/20 | 0.48 |
| ▸ | PPARA | Q07869 | 17/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5264766 | 0.96 | PPARG (0.47) | PPARGPPARATP53MAPT | |
| SCHEMBL5227770 | 0.94 | PPARG (0.45) | PPARGPPARATP53MAPT | |
| SCHEMBL5433687 | 0.93 | PPARG (0.50) | PPARGPPARA | |
| SCHEMBL5225379 | 0.93 | PPARG (0.54) | PPARGPPARATP53MAPT | |
| SCHEMBL5227508 | 0.93 | PPARA (0.49) | PPARGPPARATP53MAPT | |
| SCHEMBL5429048 | 0.90 | PPARG (0.44) | PPARGPPARATP53MAPT | |
| SCHEMBL5231626 | 0.89 | PPARG (0.49) | PPARGPPARA | |
| SCHEMBL5225872 | 0.89 | PPARG (0.52) | PPARGPPARA | |
| SCHEMBL5264954 | 0.89 | PPARG (0.48) | PPARGPPARATP53MAPT | |
| SCHEMBL5224851 | 0.89 | PPARG (0.53) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254882-A1 | Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same | CRYSTAL GENOMICS, INC. (KR) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254882-A1 | Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same | SULT2A1, SPTLC2, SGMS2 | PPARG 399/4885PPARA 190/4885TP53 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.